acne vulgaris
Women's health · 2009–2024
3decisions
2medicines
2carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| drospirenone with ethinylestradiol Oral contraception. Yaz is also TGA-registered for treatment of moderate acne vulgaris and symptoms of premenstrual dysphoric disorder (PMDD) in women using… | Nov 2024 | Recommended | 1 individuals |
| drospirenone with ethinylestradiol Oral contraception. Yaz is also TGA-registered for treatment of moderate acne vulgaris and symptoms of premenstrual dysphoric disorder (PMDD) in women using… | Nov 2024 | Recommended | 1 individuals |
| clindamycin phosphate with benzoyl peroxide, gel Treatment of moderate acne vulgaris with inflammatory lesions in patients with an inadequate response to a minimum of two over-the-counter products. | Mar 2009 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.